View prices & discounts
Free gifts
Request & accept offers online
Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARF1 (Golgi Apparatus Marker)(3F1), 0.2mg/mL | Login | ARF1 (Golgi Apparatus Marker)(3F1), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD27 (Tumor Necrosis Factor Receptor Superfamily 7) (LPFS2/2034R), 0.2mg/mL | Login | CD27 (Tumor Necrosis Factor Receptor Superfamily 7) (LPFS2/2034R), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD27 (Tumor Necrosis Factor Receptor Superfamily 7) (LPFS2/2034R), 0.2mg/mL | Login | CD27 (Tumor Necrosis Factor Receptor Superfamily 7) (LPFS2/2034R), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), 0.2mg/mL | Login | ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), 0.2mg/mL | Login | ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) (PMEL/2037), 0.2mg/mL | Login | gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) (PMEL/2037), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) (PMEL/2037), 0.2mg/mL | Login | gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) (PMEL/2037), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) (PMEL/2038), 0.2mg/mL | Login | gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) (PMEL/2038), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) (PMEL/2038), 0.2mg/mL | Login | gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) (PMEL/2038), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) (PMEL/2039), 0.2mg/mL | Login | gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) (PMEL/2039), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) (PMEL/2039), 0.2mg/mL | Login | gp100 / Melanosome / PMEL17 / SILV (Melanoma Marker) (PMEL/2039), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| EpCAM / CD326 (Epithelial Marker) (EGP40/2041R), 0.2mg/mL | Login | EpCAM / CD326 (Epithelial Marker) (EGP40/2041R), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| EpCAM / CD326 (Epithelial Marker) (EGP40/2041R), 0.2mg/mL | Login | EpCAM / CD326 (Epithelial Marker) (EGP40/2041R), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), 0.2mg/mL | Login | ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), 0.2mg/mL | Login | ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| ZAP70 (Chronic Lymphocytic Leukemia Marker)(ZAP70/2047), 0.2mg/mL | Login | ZAP70 (Chronic Lymphocytic Leukemia Marker)(ZAP70/2047), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| ZAP70 (Chronic Lymphocytic Leukemia Marker)(ZAP70/2047), 0.2mg/mL | Login | ZAP70 (Chronic Lymphocytic Leukemia Marker)(ZAP70/2047), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| Human Kappa Light Chain / IGKC (B-Cell Marker) (rKLC709), 0.2mg/mL | Login | Human Kappa Light Chain / IGKC (B-Cell Marker) (rKLC709), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| Human Kappa Light Chain / IGKC (B-Cell Marker) (rKLC709), 0.2mg/mL | Login | Human Kappa Light Chain / IGKC (B-Cell Marker) (rKLC709), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| TLE1 (Synovial Sarcoma Marker) (TLE1/2051), 0.2mg/mL | Login | TLE1 (Synovial Sarcoma Marker) (TLE1/2051), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| TLE1 (Synovial Sarcoma Marker) (TLE1/2051), 0.2mg/mL | Login | TLE1 (Synovial Sarcoma Marker) (TLE1/2051), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| Nucleophosmin (Acute Myeloid Leukemia Marker) (NA24), 0.2mg/mL | Login | Nucleophosmin (Acute Myeloid Leukemia Marker) (NA24), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| Nucleophosmin (Acute Myeloid Leukemia Marker) (NA24), 0.2mg/mL | Login | Nucleophosmin (Acute Myeloid Leukemia Marker) (NA24), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD7 (T-Cell Leukemia Marker)(CD7/3737), 0.2mg/mL | Login | CD7 (T-Cell Leukemia Marker)(CD7/3737), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD7 (T-Cell Leukemia Marker)(CD7/3737), 0.2mg/mL | Login | CD7 (T-Cell Leukemia Marker)(CD7/3737), 0.2mg/mL | ||||||||||||||||
|
||||||||||||||||||
Contact
Hölzel Diagnostika Handels GmbH
Weinsbergstr 118a
50823 Cologne
Germany
T +49 221 126 02 66
F +49 221 126 02 67
